• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Actym Therapeutics Appoints Thomas Smart as CEO

    4/24/24 9:00:00 AM ET
    $ANAB
    $PGEN
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANAB alert in real time by email

    BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

    (PRNewsfoto/Actym Therapeutics Inc.)

    Actym's proprietary platform, S. Typhimurium-Attenuated Cancer Therapy (STACT), represents a novel approach to achieving comprehensive immunological reprogramming of the tumor microenvironment. Mr. Smart's appointment follows Actym's recent presentations of preclinical data at both the 2023 SITC and 2024 AACR Annual Meetings showcasing ACTM-838's ability to selectively accumulate in the TME and locally deliver two potent payloads, engineered IL-15 and engineered STING.

    "Tom is an extremely valuable addition to Actym's leadership, bringing extensive experience in corporate development and strategic planning, coupled with a profound understanding of how to translate innovative R&D into novel therapeutics. With Tom at the helm, we are ready for our next stage of corporate growth as we close in on the start of our Phase 1 clinical development program for ACTM-838," said Julie Cherrington, Ph.D., Executive Chair of the Actym Board of Directors. "We extend our thanks to Chris Thanos for his founding contributions to the company."

    "Actym represents an exceptional opportunity to achieve a new level of therapeutic impact across multiple tumor types. In addition to moving ACTM-838 into the clinic in the second quarter, our goal is to expand our pipeline with additional candidates from Actym's modular platform. The STACT approach provides both efficacy and safety advantages by leveraging a genetically modified bacteria vehicle, systemically administered, that achieves tissue-specific delivery of large nucleic acid payloads," said Thomas Smart, CEO of Actym. "I look forward to collaborating with the Board of Directors and the entire Actym team to maximize the potential of ACTM-838 and our platform."

    Mr. Smart has a distinguished 25-year career as a biotech executive, demonstrating dynamic leadership in roles such as CEO, CBO, SVP, and Board Member. In addition, Mr. Smart has a comprehensive background in therapeutic modalities ranging from antibodies and small molecules to peptides, RNA, DNA, CAR-T, and other cell therapies. Before joining Actym Therapeutics, Mr. Smart founded Gravitas Therapeutics, where he served as CEO and Board Chair and orchestrated the acquisition and subsequent sale of the clinical-stage antifungal asset, GR-2397, to Basilea Pharmaceutica Ltd (SIX: BSLN) in October 2023. His prior leadership roles include serving as CEO and Board Chair of AnaptysBio (NASDAQ:ANAB), Chief Business Officer of XOMA (NASDAQ:XOMA), and various positions at Genetics Institute (now Pfizer), GenVec ((now Precigen, NASDAQ:PGEN), Searle (now Pfizer), and Cell Genesys. Mr. Smart holds a Bachelor of Science degree from Cornell University and earned his Master of Business Administration from the University of Chicago Booth School of Business.

    About Actym

    Actym Therapeutics has engineered a new drug modality harnessing the power of a genetically modified bacterial vehicle that safely introduces therapeutic payloads to activate the immune response in the tumor microenvironment. To achieve targeted anti-tumor effects, we have developed a systemically administered treatment that exploits intrinsic TME-specific metabolites, enabling selective enrichment of the bacterial vehicle in tumors. After cell-specific entry, our lead candidate, ACTM-838, positively activates tumor-resident myeloid cells and delivers two synergistic payloads, optimized IL-15 and STING, unlocking a comprehensive and durable innate and adaptive anti-tumor immune response. With the ability to tailor our platform utilizing a range of payload combinations, we aim to achieve a new level of therapeutic impact for cancer patients across multiple tumor types.

    Contacts

    For Actym Therapeutics

    Thomas E. Smart, CEO

    E-Mail: [email protected]

    Media Requests for Actym

    Dr. Alison Opalko or Sara Ortiz

    Trophic Communications

    Phone: +49 151 54041130 or +49 160 90816161

    E-Mail: [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/actym-therapeutics-appoints-thomas-smart-as-ceo-302125751.html

    SOURCE Actym Therapeutics Inc.

    Get the next $ANAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANAB
    $PGEN
    $XOMA

    CompanyDatePrice TargetRatingAnalyst
    XOMA Royalty Corporation
    $XOMA
    4/17/2025$35.00Buy
    The Benchmark Company
    AnaptysBio Inc.
    $ANAB
    2/4/2025$25.00Outperform
    Wolfe Research
    AnaptysBio Inc.
    $ANAB
    12/11/2024$52.00 → $19.00Buy → Neutral
    H.C. Wainwright
    AnaptysBio Inc.
    $ANAB
    12/2/2024Buy → Neutral
    BTIG Research
    AnaptysBio Inc.
    $ANAB
    7/22/2024$55.00Buy
    H.C. Wainwright
    AnaptysBio Inc.
    $ANAB
    7/19/2024$29.00 → $69.00Neutral → Overweight
    JP Morgan
    XOMA Royalty Corporation
    $XOMA
    4/29/2024$40.00Outperform
    Leerink Partners
    AnaptysBio Inc.
    $ANAB
    4/16/2024$47.00Outperform
    Leerink Partners
    More analyst ratings

    $ANAB
    $PGEN
    $XOMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Benchmark Company initiated coverage on XOMA Royalty Corporation with a new price target

      The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00

      4/17/25 8:34:06 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on AnaptysBio with a new price target

      Wolfe Research initiated coverage of AnaptysBio with a rating of Outperform and set a new price target of $25.00

      2/4/25 6:58:43 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded AnaptysBio from Buy to Neutral and set a new price target of $19.00 from $52.00 previously

      12/11/24 12:23:14 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    $PGEN
    $XOMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Investment Officer Sitko Bradley bought $49,400 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $24.70), increasing direct ownership by 66% to 5,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/9/25 4:44:30 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Limber Joseph M bought $504,504 worth of Depositary Shares - 8.375% Series B Cumulative Stock (20,000 units at $25.23) and bought $255,640 worth of 8.625% Series A Cumulative Perpetual Preferred Stock (10,000 units at $25.56) (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/7/25 4:39:59 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Investment Officer Sitko Bradley bought $19,980 worth of shares (1,000 units at $19.98) and bought $6,221 worth of Depositary Shares - 8.375% Series B Perpetual Preferred (245 units at $25.39), decreasing direct ownership by 71% to 3,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/2/25 4:30:27 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    $PGEN
    $XOMA
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Precigen Inc.

      PRE 14A - PRECIGEN, INC. (0001356090) (Filer)

      5/6/25 4:15:29 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by AnaptysBio Inc.

      10-Q - ANAPTYSBIO, INC (0001370053) (Filer)

      5/5/25 4:19:46 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ANAPTYSBIO, INC (0001370053) (Filer)

      5/5/25 4:17:51 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    $PGEN
    $XOMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

      SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      11/14/24 4:00:05 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

      SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      11/14/24 9:24:47 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by AnaptysBio Inc.

      SC 13D/A - ANAPTYSBIO, INC (0001370053) (Subject)

      8/16/24 12:07:11 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    $PGEN
    $XOMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Tennant Phil

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      4/18/25 5:06:44 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Shah Rutul R

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      4/18/25 5:02:52 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Lehr Donald P.

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      4/18/25 5:02:35 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    $PGEN
    $XOMA
    Financials

    Live finance-specific insights

    See more
    • XOMA Royalty Completes Sale of Kinnate Pipeline Assets

      XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related upfront, milestone, and royalty payments paid to XOMA Royalty prior to April 2, 2029 EMERYVILLE, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has completed the sale of all five pipeline assets that were acquired when XOMA Royalty closed its acquisition of Kinnate Biopharma Inc. on April 3, 2024.

      4/14/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty Declares Quarterly Preferred Stock Dividends

      EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.  Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about April 15, 2025, to respe

      3/20/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

      GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu

      3/13/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    $PGEN
    $XOMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

      EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference being held May 13, 2025. Mr. Hughes and Mr. Sitko will participate in a fireside chat at 2:30 PM ET.  Mr. Hughes will join the "Pros and Cons of Royalty Model – Especially in Current Financing Environment" panel discussion at 4:00 PM ET.  Mr. Sitko will participate in the "Development-Stage Companies – Where do Royalty and Tech Platforms Play Fit?" panel at 5:00 PM ET.  

      5/7/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

      Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of JuneInitial Phase 2 data for rosnilimab in ulcerative colitis (UC) on track for Q4 2025Ongoing Phase 1a trials in healthy volunteers for ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulatorAuthorized a $75 million Stock Repurchase Program in March 2025 and reiterating cash runway through year-end 2027 SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, tod

      5/5/25 4:15:00 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services

    $ANAB
    $PGEN
    $XOMA
    Leadership Updates

    Live Leadership Updates

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

      – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

      4/16/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

      –  Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 Aden

      7/23/24 8:01:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care